Denifanstat (ASC40)

About Sagimet Biosciences

Sagimet Biosciences is pioneering a novel therapeutic approach by selectively inhibiting the fatty acid synthase (FASN) enzyme, a key regulator of lipid synthesis implicated in multiple diseases. The company's lead asset, denifanstat, has demonstrated statistically significant efficacy in a Phase 2b MASH trial and met all endpoints in a Phase 3 acne trial, supported by FDA Breakthrough Therapy designation for MASH. With a pipeline extending to oncology and a second FASN inhibitor, TVB-3567, entering clinical development for acne, Sagimet is positioned to address significant unmet needs in metabolic, dermatological, and oncological diseases.

About Sagimet Biosciences

Sagimet Biosciences is pioneering a novel therapeutic approach by selectively inhibiting the fatty acid synthase (FASN) enzyme, a key regulator of lipid synthesis implicated in multiple diseases. The company's lead asset, denifanstat, has demonstrated statistically significant efficacy in a Phase 2b MASH trial and met all endpoints in a Phase 3 acne trial, supported by FDA Breakthrough Therapy designation for MASH. With a pipeline extending to oncology and a second FASN inhibitor, TVB-3567, entering clinical development for acne, Sagimet is positioned to address significant unmet needs in metabolic, dermatological, and oncological diseases.

Therapeutic Areas